ClariTrial | Search Clinical Trials

Explore/neurology CNS brain disease

Status

Phase

Pre-filtered to show active, later-stage trials with the strongest clinical signal.

162 results for “neurology CNS brain disease” · Recruiting · Phase 3 · Phase 2

Page 1 of 11

Recruiting

A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)

Phase 3Alzheimer Disease

Xanomeline/Trospium Chloride CapsuleXanomeline Enteric CapsulePlacebo

Bristol-Myers Squibb352 participants157 sites · United States, Argentina, BrazilCompletes Nov 2028

Compare CT.gov Full analysis →

Recruiting

Clinical Trial on Agitation in Alzheimer's Dementia

Phase 2Alzheimer DiseaseAgitation,PsychomotorCare Giving Burden

IGC-AD1-ActiveIGC-AD1-Placebo

IGC Pharma, LLC164 participants31 sites · United States, Canada, ColombiaCompletes Aug 2026

Compare CT.gov Full analysis →

Recruiting

Combining Aspirin With Cilostazol or Clopidogrel in Large-vessel Minor Stroke or TIA

Phase 3Ischemic Stroke

Cilostazol 100 MGClopidogrel

Kafrelsheikh University870 participants1 site · EgyptCompletes Sep 2024

Compare CT.gov Full analysis →

Recruiting

A Study to Investigate the Safety and Efficacy of MEDI0618 Compared to Placebo in Adult Participants With Episodic Migraine

Phase 2Migraine

MEDI0618Placebo

AbbVie488 participants54 sites · United States, Czechia, DenmarkCompletes Dec 2026

Compare CT.gov Full analysis →

Recruiting

A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder

Phase 3Major Depressive Disorder (MDD)Depression in AdultsDepression - Major Depressive Disorder

CYB003Psychological Support

Cybin IRL Limited330 participants67 sites · United States, Australia, CzechiaCompletes Mar 2027

Compare CT.gov Full analysis →

Recruiting

Communication Bridge 3 Study

Phase 2Primary Progressive Aphasia

Communication Bridge™Evidence-Based Impairment Focused

University of Chicago200 participants1 site · United StatesCompletes Jul 2028

Compare CT.gov Full analysis →

Recruiting

A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity

Phase 2Multiple Sclerosis Spasticity

BMS-986368Placebo

Celgene200 participants54 sites · United States, Australia, CanadaCompletes May 2027

Compare CT.gov Full analysis →

Recruiting

Combining Aspirin With Ticagrelor or Cilostazol in Large-vessel Minor Stroke or TIA

Phase 3Ischemic Stroke

Ticagrelor 90 MGCilostazol 100 MGAspirin 75mg+1 more

Kafrelsheikh University900 participants2 sites · EgyptCompletes Sep 2025

Compare CT.gov Full analysis →

Recruiting

Efficacy and Safety of Baricitinib in Neuromyelitis Optica Spectrum Disorders

Phase 1Phase 2NMO Spectrum Disorder

Baricitinib

Tianjin Medical University General Hospital12 participants1 site · ChinaCompletes Dec 2025

Compare CT.gov Full analysis →

Recruiting

Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine

Phase 3Acute Treatment of Migraine

Rimegepant (PF-07899801)

Pfizer600 participants126 sites · United States, Poland, SpainCompletes Jul 2030

Compare CT.gov Full analysis →

Recruiting

Combining Use of Clopidogrel With Atorvastatin or Rosuvastatin in Patients With Large-vessel Ischemic Stroke

Phase 3Ischemic Stroke

Atorvastatin 40 Mg Oral TabletRosuvastatin 20mgClopidogrel 75 Mg Oral Tablet+1 more

Kafrelsheikh University600 participants1 site · EgyptCompletes Sep 2025

Compare CT.gov Full analysis →

Recruiting

Tenecteplase for Intravenous Stroke Thrombolysis in Recent DOAC Users

Phase 3Acute Ischemic Stroke

Tenecteplase (TNK) (0.25 mg/kg, to maximum of 25mg)Placebo

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University912 participants1 site · ChinaCompletes Sep 2028

Compare CT.gov Full analysis →

Recruiting

ALA-enriched Nutrition for Prevention of Cognitive Decline in APOE4 Older Adults

Phase 2Cognitive DysfunctionAlzheimer DiseaseBlood-Brain Barrier

Alpha-Linolenic Acid (2.6 g/day)Placebo Control Group

Michal Schnaider Beeri, Ph.D.20 participants1 site · United StatesCompletes Apr 2027

Compare CT.gov Full analysis →

Recruiting

Cladribine vs Placebo for Non-active Progressive Multiple Sclerosis (CLASP-MS).

Phase 2Phase 3Multiple Sclerosis, Secondary ProgressiveMultiple Sclerosis

Cladribine Subcutaneous Injection0.9% Chloride Injection Sodium

Institute of Psychiatry and Neurology, Warsaw188 participants1 site · PolandCompletes Jun 2027

Compare CT.gov Full analysis →

Recruiting

Promoting Recovery After STroke With Amantadine

Phase 2Stroke, IschemicStroke Hemorrhagic

AmantadinePlacebo

University of Pennsylvania60 participants1 site · United StatesCompletes Dec 2027

Compare CT.gov Full analysis →

1–15 of 162

Explore/neurology CNS brain disease

Status

Phase

Pre-filtered to show active, later-stage trials with the strongest clinical signal.

162 results for “neurology CNS brain disease” · Recruiting · Phase 3 · Phase 2

Page 1 of 11

Recruiting

A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)

Phase 3Alzheimer Disease

Xanomeline/Trospium Chloride CapsuleXanomeline Enteric CapsulePlacebo

Bristol-Myers Squibb352 participants157 sites · United States, Argentina, BrazilCompletes Nov 2028

Compare CT.gov Full analysis →

Recruiting

Clinical Trial on Agitation in Alzheimer's Dementia

Phase 2Alzheimer DiseaseAgitation,PsychomotorCare Giving Burden

IGC-AD1-ActiveIGC-AD1-Placebo

IGC Pharma, LLC164 participants31 sites · United States, Canada, ColombiaCompletes Aug 2026

Compare CT.gov Full analysis →

Recruiting

Combining Aspirin With Cilostazol or Clopidogrel in Large-vessel Minor Stroke or TIA

Phase 3Ischemic Stroke

Cilostazol 100 MGClopidogrel

Kafrelsheikh University870 participants1 site · EgyptCompletes Sep 2024

Compare CT.gov Full analysis →

Recruiting

A Study to Investigate the Safety and Efficacy of MEDI0618 Compared to Placebo in Adult Participants With Episodic Migraine

Phase 2Migraine

MEDI0618Placebo

AbbVie488 participants54 sites · United States, Czechia, DenmarkCompletes Dec 2026

Compare CT.gov Full analysis →

Recruiting

A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder

Phase 3Major Depressive Disorder (MDD)Depression in AdultsDepression - Major Depressive Disorder

CYB003Psychological Support

Cybin IRL Limited330 participants67 sites · United States, Australia, CzechiaCompletes Mar 2027

Compare CT.gov Full analysis →

Recruiting

Communication Bridge 3 Study

Phase 2Primary Progressive Aphasia

Communication Bridge™Evidence-Based Impairment Focused

University of Chicago200 participants1 site · United StatesCompletes Jul 2028

Compare CT.gov Full analysis →

Recruiting

A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity

Phase 2Multiple Sclerosis Spasticity

BMS-986368Placebo

Celgene200 participants54 sites · United States, Australia, CanadaCompletes May 2027

Compare CT.gov Full analysis →

Recruiting

Combining Aspirin With Ticagrelor or Cilostazol in Large-vessel Minor Stroke or TIA

Phase 3Ischemic Stroke

Ticagrelor 90 MGCilostazol 100 MGAspirin 75mg+1 more

Kafrelsheikh University900 participants2 sites · EgyptCompletes Sep 2025

Compare CT.gov Full analysis →

Recruiting

Efficacy and Safety of Baricitinib in Neuromyelitis Optica Spectrum Disorders

Phase 1Phase 2NMO Spectrum Disorder

Baricitinib

Tianjin Medical University General Hospital12 participants1 site · ChinaCompletes Dec 2025

Compare CT.gov Full analysis →

Recruiting

Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine

Phase 3Acute Treatment of Migraine

Rimegepant (PF-07899801)

Pfizer600 participants126 sites · United States, Poland, SpainCompletes Jul 2030

Compare CT.gov Full analysis →

Recruiting

Combining Use of Clopidogrel With Atorvastatin or Rosuvastatin in Patients With Large-vessel Ischemic Stroke

Phase 3Ischemic Stroke

Atorvastatin 40 Mg Oral TabletRosuvastatin 20mgClopidogrel 75 Mg Oral Tablet+1 more

Kafrelsheikh University600 participants1 site · EgyptCompletes Sep 2025

Compare CT.gov Full analysis →

Recruiting

Tenecteplase for Intravenous Stroke Thrombolysis in Recent DOAC Users

Phase 3Acute Ischemic Stroke

Tenecteplase (TNK) (0.25 mg/kg, to maximum of 25mg)Placebo

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University912 participants1 site · ChinaCompletes Sep 2028

Compare CT.gov Full analysis →

Recruiting

ALA-enriched Nutrition for Prevention of Cognitive Decline in APOE4 Older Adults

Phase 2Cognitive DysfunctionAlzheimer DiseaseBlood-Brain Barrier

Alpha-Linolenic Acid (2.6 g/day)Placebo Control Group

Michal Schnaider Beeri, Ph.D.20 participants1 site · United StatesCompletes Apr 2027

Compare CT.gov Full analysis →

Recruiting

Cladribine vs Placebo for Non-active Progressive Multiple Sclerosis (CLASP-MS).

Phase 2Phase 3Multiple Sclerosis, Secondary ProgressiveMultiple Sclerosis

Cladribine Subcutaneous Injection0.9% Chloride Injection Sodium

Institute of Psychiatry and Neurology, Warsaw188 participants1 site · PolandCompletes Jun 2027

Compare CT.gov Full analysis →

Recruiting

Promoting Recovery After STroke With Amantadine

Phase 2Stroke, IschemicStroke Hemorrhagic

AmantadinePlacebo

University of Pennsylvania60 participants1 site · United StatesCompletes Dec 2027

Compare CT.gov Full analysis →

1–15 of 162